|
|
|
01 Sep 2010 |
EC Regulator Rubber-Stamps Archimedes Pharma’s Intranasal Fentanyl Spray for Cancer Pain
|
29 |
|
01 Sep 2010 |
QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuoIR
|
26 |
|
01 Sep 2010 |
Aegis' ProTek(R) Excipients Prevent Aggregation and Eliminate Unwanted beta-Interferon Immunogenicity
|
23 |
|
01 Sep 2010 |
Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
|
30 |
|
01 Sep 2010 |
ReVision's Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
|
18 |
|
01 Sep 2010 |
Inhibitex Successfully Completes Phase 1a Trial of INX-189
|
22 |
|
01 Sep 2010 |
Lytix Biopharma AS Announces Approval by Hungarian Authorities and Ethics Committee to Start Phase IIa Clinical Trial with LytixarTM (LTX-109) in Gram Positive Skin Infections
|
21 |
|
01 Sep 2010 |
Afferent Pharmaceuticals Presents Data Supporting Use of P2X3 Antagonists in Reducing Bone Cancer Pain
|
21 |
|
01 Sep 2010 |
Concordia Pharmaceuticals, Inc. Signs First Licensing Agreement with Ono Pharmaceutical Co, Ltd. for Salirasib
|
21 |
|
31 Aug 2010 |
GlaxoSmithKline (GSK), Valeant Pharmaceuticals International (VRX) Face US Delay for Epilepsy Drug, Receives New PDUFA
|
44 |
|
31 Aug 2010 |
MonoSol Rx Announces Reckitt Benckiser FDA Approval of Suboxone Sublingual Film for Treatment of Opioid Dependence
|
42 |
|
31 Aug 2010 |
Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch
|
27 |
|
31 Aug 2010 |
Neurotech Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial for AAD-2004, a Potent Spin Trapping Molecule and Microsomal Prostaglandin E Synthase-1 Inhibitor, Targeting Alzheimer's, Parkinson's, and Lou Gehrig's Disease
|
30 |
|
31 Aug 2010 |
Alimera Sciences' Iluvien(R) Receives FDA Priority Review for the Treatment of Diabetic Macular Edema
|
38 |
|
31 Aug 2010 |
Ovatech reports successful completion of Phase 2 clinical trial of Ovaprene non-hormonal intravaginal contraceptive ring
|
25 |
|
31 Aug 2010 |
Bionovo Receives Positive Guidance from FDA on Menerba
|
31 |
|
31 Aug 2010 |
Achaogen Awarded Contract Worth up to $64 Million by Biomedical Advanced Research and Development Authority (BARDA) for the Development of ACHN-490
|
25 |
|
31 Aug 2010 |
Combination Therapy of Telmisartan and Amlodipine Provides Significantly Better Blood Pressure Lowering Than Either Agent Alone
|
51 |
|
31 Aug 2010 |
Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
|
32 |
|
31 Aug 2010 |
CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
|
32 |
|
30 Aug 2010 |
Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the Treatment of Bipolar Depression
|
40 |
|
30 Aug 2010 |
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
|
36 |
|
30 Aug 2010 |
Pre and Post-Operative Use of Caldolor (Ibuprofen) Injection Significantly Reduces Pain and Opioid Use in Newly Published Study
|
37 |
|
30 Aug 2010 |
BEMA Buprenorphine Phase 2 Study Results Selected for Presentation at Pain Week 2010
|
31 |
|
30 Aug 2010 |
Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain
|
33 |
|
30 Aug 2010 |
Glenmark announces the Discovery of a novel chemical entity 'GRC 17536', a potential first-in-class molecule globally
|
49 |
|
30 Aug 2010 |
KYTHERA and Bayer Dermatology Unit Intendis Enter Licensing and Development Agreement for Adipolytic Agent ATX-101
|
37 |
|
30 Aug 2010 |
Trius Therapeutics Initiates Phase 3 Program of Oral Torezolid Phosphate for the Treatment of ABSSSI
|
33 |
|
30 Aug 2010 |
Medicis Announces Approval of Additional Strengths of Solodyn(R)
|
30 |
|
30 Aug 2010 |
Eisai Announces Extension of FDA Review of Drug Application for Investigational Agent Eribulin Mesylate
|
44 |
| |
|
Results 1 - 30 of 9029 |
